Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization

Journal of Controlled Release

Volumn 159, Issue 1, 2012, Pages 27-33

  Kleinedler, James J ^a   Foley, John D ^b   Orchard, Elysse A ^a   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Nanocopoeia Inc   (United States)

Author keywords

Artery; Drug eluting stent; Endothelium; Polyphenol; Restenosis

Indexed keywords

ARTERY; DRUG-ELUTING STENT; ENDOTHELIUM; POLYPHENOLS; RESTENOSIS;

ARTIFICIAL ORGANS; DISEASES; ENDOTHELIAL CELLS; FATTY ACIDS; NANOCOMPOSITES; PHENOLS; SPRAYED COATINGS;

STENTS;

NANOCOATING; NANOCOMPOSITE; QUERCETIN; RESVERATROL;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; CELL INFILTRATION; COMMON CAROTID ARTERY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; EXTERNAL CAROTID ARTERY; EXTRACELLULAR MATRIX; FEMALE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN-STENT RESTENOSIS; MACROPHAGE; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ACTIVATION;

ANGIOPLASTY; ANIMALS; ANTIMITOTIC AGENTS; CELL PROLIFERATION; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HYPERPLASIA; MALE; NANOCOMPOSITES; NEOINTIMA; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 84859486576     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.008     Document Type: Article

References (61)

1. A.H. Kragel, S.G. Reddy, J.T. Wittes, and W.C. Roberts Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death Circulation 80 6 1989 1747 1756
2. M.N. Babapulle, and M.J. Eisenberg Coated stents for the prevention of restenosis: Part I Circulation 106 21 2002 2734 2740
3. A. Farb, G. Sangiorgi, A.J. Carter, V.M. Walley, W.D. Edwards, R.S. Schwartz, and R. Virmani Pathology of acute and chronic coronary stenting in humans Circulation 99 1 1999 44 52
4. D.P. Faxon, W. Coats, and J. Currier Remodeling of the coronary artery after vascular injury Prog. Cardiovasc. Dis. 40 2 1997 129 140
5. R.W. Sirianni, E.H. Jang, K.M. Miller, and W.M. Saltzman Parameter estimation methodology in a model of hydrophobic drug release from a polymer coating J. Control. Release 142 3 2010 474 482
6. R.A. Byrne, N. Sarafoff, A. Kastrati, and A. Schomig Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment Drug Saf. 32 9 2009 749 770
7. G. Nakazawa, A.V. Finn, F.D. Kolodgie, and R. Virmani A review of current devices and a look at new technology: drug-eluting stents Expert Rev. Med. Devices 6 1 2009 33 42
8. W.J. van der Giessen, A.M. Lincoff, R.S. Schwartz, H.M. van Beusekom, P.W. Serruys, D.R. Holmes Jr., S.G. Ellis, and E.J. Topol Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 7 1996 1690 1697
9. C. Stettler, S. Wandel, S. Allemann, A. Kastrati, M.C. Morice, A. Schomig, M.E. Pfisterer, G.W. Stone, M.B. Leon, J.S. de Lezo, J.J. Goy, S.J. Park, M. Sabate, M.J. Suttorp, H. Kelbaek, C. Spaulding, M. Menichelli, P. Vermeersch, M.T. Dirksen, P. Cervinka, A.S. Petronio, A.J. Nordmann, P. Diem, B. Meier, M. Zwahlen, S. Reichenbach, S. Trelle, S. Windecker, and P. Juni Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 9591 2007 937 948
10. R.J. Krone, S.V. Rao, D. Dai, H.V. Anderson, E.D. Peterson, M.A. Brown, R.G. Brindis, L.W. Klein, R.E. Shaw, and W.S. Weintraub Acceptance, panic, and partial recovery the pattern of usage of drug-eluting stents after introduction in the U.S. (a report from the American College of Cardiology/National Cardiovascular Data Registry) JACC Cardiovasc. Interv. 3 9 2010 902 910
11. M. Shuchman Trading restenosis for thrombosis? New questions about drug-eluting stents N. Engl. J. Med. 355 19 2006 1949 1952
12. R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, L. Mihalcsik, M. Tespili, O. Valsecchi, and F.D. Kolodgie Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 6 2004 701 705
13. A.V. Finn, F.D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D.K. Weber, H.K. Gold, and R. Virmani Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents Circulation 112 2 2005 270 278
14. J.M. de la Torre Hernandez, F. Alfonso, F. Gimeno, J.A. Diarte, R. Lopez-Palop, A. Perez de Prado, F. Rivero, J. Sanchis, M. Larman, J.F. Diaz, J. Elizaga, J.M. Moreiras, A. Gomez Jaume, J.M. Hernandez, J. Mauri, A.S. Recalde, J.A. Bullones, J.R. Rumoroso, B.G. Del Blanco, J.A. Baz, F. Bosa, J. Botas, and F. Hernandez Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2) JACC Cardiovasc. Interv. 3 9 2010 911 919
15. K. Rasmussen, M. Maeng, A. Kaltoft, P. Thayssen, H. Kelbaek, H.H. Tilsted, U. Abildgaard, E.H. Christiansen, T. Engstrom, L.R. Krusell, J. Ravkilde, P.R. Hansen, K.N. Hansen, S.Z. Abildstrom, J. Aaroe, J.S. Jensen, S.D. Kristensen, H.E. Botker, M. Madsen, S.P. Johnsen, L.O. Jensen, H.T. Sorensen, L. Thuesen, and J.F. Lassen Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 9720 2010 1090 1099
16. R. Martin-Rayes, R. Moreno, P.S. Sanguino, A. Sanchez-Recalde, and J.L.L. Sendon Evaluation of the safety of drug eluting stents between first and second generation: meta-analysis of 17 randomized trials and 11,000 patients Circulation 120 2009 S980 S981
17. A. Kraitzer, L. Ofek, R. Schreiber, and M. Zilberman Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures J. Control. Release 126 2 2008 139 148
18. J. Jakabcin, M. Bystron, R. Spacek, J. Veselka, M. Kvasnak, P. Kala, J. Maly, and P. Cervinka The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis J. Thromb. Thrombolysis 26 2 2008 154 158
19. A.V. Finn, G. Nakazawa, M. Joner, F.D. Kolodgie, E.K. Mont, H.K. Gold, and R. Virmani Vascular responses to drug eluting stents: importance of delayed healing Arterioscler. Thromb. Vasc. Biol. 27 7 2007 1500 1510
20. M. Vorpahl, S.K. Yazdani, M. Nakano, E. Ladich, F.D. Kolodgie, A.V. Finn, and R. Virmani Pathobiology of stent thrombosis after drug-eluting stent implantation Curr. Pharm. Des. 16 36 2010 4064 4071
21. A.V. Finn, H.K. Gold, A. Tang, D.K. Weber, T.N. Wight, A. Clermont, R. Virmani, and F.D. Kolodgie A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic diseases J. Vasc. Res. 39 5 2002 414 425
22. B. Lee, and S.K. Moon Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells J. Nutr. 135 12 2005 2767 2773
23. S.K. Moon, G.O. Cho, S.Y. Jung, S.W. Gal, T.K. Kwon, Y.C. Lee, N.R. Madamanchi, and C.H. Kim Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9 Biochem. Biophys. Res. Commun. 301 4 2003 1069 1078
24. A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition Am. J. Physiol. Heart Circ. Physiol. 291 4 2006 H1694 H1699
25. G.P. Hubbard, S. Wolffram, J.A. Lovegrove, and J.M. Gibbins Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans J. Thromb. Haemost. 2 12 2004 2138 2145
26. K. Ishizawa, Y. Izawa-Ishizawa, S. Ohnishi, Y. Motobayashi, K. Kawazoe, S. Hamano, K. Tsuchiya, S. Tomita, K. Minakuchi, and T. Tamaki Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells J. Pharmacol. Sci. 109 2 2009 257 264
27. B.F. Huang, W. Wang, Y.C. Fu, X.H. Zhou, and X. Wang The effect of quercetin on neointima formation in a rat artery balloon injury model Pathol. Res. Pract. 205 8 2009 515 523
28. A.R. Khandelwal, V.Y. Hebert, and T.R. Dugas Essential role of ER-alpha-dependent NO production in resveratrol-mediated inhibition of restenosis Am. J. Physiol. Heart Circ. Physiol. 299 5 2010 H1451 1458
29. J.J. Kleinedler, J.D. Foley, J.S. Alexander, S.C. Roerig, V.Y. Hebert, and T.R. Dugas Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices J. Biomed. Mater. Res. B. Appl. Biomater. 99 2 2011 266 275
30. M. Sanchez, F. Lodi, R. Vera, I.C. Villar, A. Cogolludo, R. Jimenez, L. Moreno, M. Romero, J. Tamargo, F. Perez-Vizcaino, and J. Duarte Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta J. Nutr. 137 4 2007 910 915
31. G.J.W. Cq, F. Hh, D. Hy, X. Xl, X. Ym, W. By, and H. Dj Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats J. Cardiovasc. Pharmacol. 47 5 2006 711 721
32. J.J. Kleinedler, E.A. Orchard, J.D. Foley, L.K. Rogers, V.Y. Hebert, and T.R. Dugas A dietary approach to increase in-stent stenosis and face validity of a rat model for arterial angioplasty and stenting Atherosclerosis 219 2 2011 484 491
33. M.C. John, R. Wessely, A. Kastrati, A. Schomig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F.D. Kolodgie, H.K. Gold, R. Virmani, and A.V. Finn Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents JACC Cardiovasc. Interv. 1 5 2008 535 544
34. J. Dong, J.D. Foley, C.D. Frethem, R.A. Hoerr, M.J. Matuszewski, J.E. Puskas, and G. Haugstad Multimodal dynamic imaging of therapeutic biomedical coatings in aqueous medium Langmuir 25 10 2009 5442 5445
35. J.E. Puskas, L.G. Munoz-Robledo, R.A. Hoerr, J. Foley, S.P. Schmidt, M. Evancho-Chapman, J. Dong, C. Frethem, and G. Haugstad Drug-eluting stent coatings Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1 4 2009 451 462
36. J.E. Puskas, C. Paulo, and V. Altstadt Mechanical and Viscoelastic Characterization of Hyperbranched Polyisobutylenes Rubber Chem. Technol. 75 5 2002 12
37. J.E. Puskas, Y. Kwon, P. Antony, and A.K. Bhowmick Synthesis and characterization of novel dendritic (arborescent, hyperbranched) polyisobutylene-polystyrene block copolymers J. Polym. Sci., Part A: Polym. Chem. 43 9 2005 1811 1826
38. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
39. C. Uyan, H. Arinc, H. Gunduz, and R. Akdemir Immediate and six months clinical and angiographic results of intracoronary paclitaxel-coated stent implantation - the Meo:DrugStar-1 study Vasc. Health Risk Manage. 4 1 2008 173 176
40. K. Kolandaivelu, R. Swaminathan, W.J. Gibson, V.B. Kolachalama, K.L. Nguyen-Ehrenreich, V.L. Giddings, L. Coleman, G.K. Wong, and E.R. Edelman Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 13 2011 1400 1409
41. J.F. Granada, S. Inami, M.S. Aboodi, A. Tellez, K. Milewski, D. Wallace-Bradley, S. Parker, S. Rowland, G. Nakazawa, M. Vorpahl, F.D. Kolodgie, G.L. Kaluza, M.B. Leon, and R. Virmani Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix Circ. Cardiovasc. Interv. 3 3 2010 257 266
42. M. Joner, K. Morimoto, H. Kasukawa, K. Steigerwald, S. Merl, G. Nakazawa, M.C. John, A.V. Finn, E. Acampado, F.D. Kolodgie, H.K. Gold, and R. Virmani Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma Arterioscler. Thromb. Vasc. Biol. 28 11 2008 1960 1966
43. A.W. Heldman, L. Cheng, G.M. Jenkins, P.F. Heller, D.W. Kim, M. Ware Jr., C. Nater, R.H. Hruban, B. Rezai, B.S. Abella, K.E. Bunge, J.L. Kinsella, S.J. Sollott, E.G. Lakatta, J.A. Brinker, W.L. Hunter, and J.P. Froehlich Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis Circulation 103 18 2001 2289 2295
44. A. Farb, A.L. Tang, S. Shroff, W. Sweet, and R. Virmani Neointimal responses 3 months after (32)P beta-emitting stent placement Int. J. Radiat. Oncol. Biol. Phys. 48 3 2000 889 898
45. T. Asahara, C. Bauters, C. Pastore, M. Kearney, S. Rossow, S. Bunting, N. Ferrara, J.F. Symes, and J.M. Isner Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery Circulation 91 11 1995 2793 2801
46. G. Sandhu, B. Doyle, R. Singh, M. Bell, J. Bresnahan, V. Mathew, D. Holmes, A. Lerman, and C. Rihal Frequency, etiology, treatment, and outcomes of drug-eluting stent thrombosis during one year of follow-up Am. J. Cardiol. 99 4 2007 465 469
47. R.E. Scharf, and L.A. Harker Thrombosis and atherosclerosis: regulatory role of interactions among blood components and endothelium Blut 55 3 1987 131 144
48. P.H. Grewe, T. Deneke, A. Machraoui, J. Barmeyer, and K.M. Muller Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen J. Am. Coll. Cardiol. 35 1 2000 157 163
49. M.L. Balestrieri, C. Schiano, F. Felice, A. Casamassimi, A. Balestrieri, L. Milone, L. Servillo, and C. Napoli Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells J. Biochem. 143 2 2008 179 186
50. M. Takano, T. Ohba, S. Inami, K. Seimiya, S. Sakai, and K. Mizuno Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation Eur. Heart J. 27 18 2006 2189 2195
51. M. Hara, M. Nishino, M. Taniike, N. Makino, H. Kato, Y. Egami, R. Shutta, H. Yamaguchi, J. Tanouchi, and Y. Yamada Difference of neointimal formational pattern and incidence of thrombus formation among 3 kinds of stents: an angioscopic study JACC Cardiovasc. Interv. 3 2 2010 215 220
52. C. Rogers, F.G. Welt, M.J. Karnovsky, and E.R. Edelman Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin Arterioscler. Thromb. Vasc. Biol. 16 10 1996 1312 1318
53. V.P. Ekshyyan, V.Y. Hebert, A. Khandelwal, and T.R. Dugas Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production J. Cardiovasc. Pharmacol. 50 1 2007 83 93
54. M.Y. Shen, G. Hsiao, C.L. Liu, T.H. Fong, K.H. Lin, D.S. Chou, and J.R. Sheu Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP Br. J. Haematol. 139 3 2007 475 485
55. J.V. Formica, and W. Regelson Review of the biology of Quercetin and related bioflavonoids Food Chem. Toxicol. 33 12 1995 1061 1080
56. M. Kyaw, M. Yoshizumi, K. Tsuchiya, Y. Izawa, Y. Kanematsu, and T. Tamaki Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases Acta Pharmacol. Sin. 25 8 2004 977 985
57. M. Sanchez, M. Galisteo, R. Vera, I.C. Villar, A. Zarzuelo, J. Tamargo, F. Perez-Vizcaino, and J. Duarte Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats J. Hypertens. 24 1 2006 75 84
58. T. Wallerath, G. Deckert, T. Ternes, H. Anderson, H. Li, K. Witte, and U. Forstermann Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase Circulation 106 13 2002 1652 1658
59. M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H.K. Gold, and R. Virmani Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J. Am. Coll. Cardiol. 48 1 2006 193 202
60. R.S. Schwartz, N.A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: still important, still much to learn J. Am. Coll. Cardiol. 44 7 2004 1373 1385
61. A.G. Touchard, and R.S. Schwartz Preclinical restenosis models: challenges and successes Toxicol. Pathol. 34 1 2006 11 18